Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type
Clinical trial NCT02906150 · UNKNOWN
Trial details
- NCT number
- NCT02906150
- Sponsor
- SciClone Pharmaceuticals
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-01
- Primary completion
- 2019-05-01
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.